In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina Goes Consumer

Executive Summary

Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.

You may also be interested in...



With Helix, Illumina Goes Consumer – Again

After failing to tap into the consumer market six years ago with a health-information-oriented Personal Genomics Service, Illumina is taking a new tack in trying to leverage the value of its industry-leading gene sequencing platform – in this case setting its sights well beyond medicine and even wellness. Its new $100 million venture, Helix, also backed by two large investors, intends to become a massive “app store,” with partners creating content derived from consumers’ genomic information.

Which Path Forward For Foundation Medicine?

Now backed by Roche, can Foundation Medicine continue to innovate in the delivery of molecular information in oncology and outpace the twin threats posed by the commoditization and regulation of genomic data?

Clinical Cancer Genomics Gives Bioinformatics Businesses A Boost

New products are combining genomic information with drug and clinical data to help oncologists make better treatment decisions. Buoyed largely by demand in oncology, is the time ripe to build lasting companies on bioinformatics platforms?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel